Finerenone study for heart thickening
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests if a medication called finerenone can improve heart structure and function in people whose heart walls are thickened. It may help people with early heart failure or related conditions like diabetes or kidney disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and willing to give written consent.
- You have a recent echocardiogram or MRI showing that your heart is thickened or heavier than normal (specific measurements apply).
- You have at least one of these: history of heart failure with preserved pumping function, type 2 diabetes, mild-to-moderate kidney disease, or certain other heart-related markers.
- You are not currently taking a specific blood pressure medication called a mineralocorticoid receptor antagonist (e.g., spironolactone).
- You do not have severe kidney disease, high potassium levels, or a pacemaker/defibrillator.
- You have not had a heart attack, heart surgery, or stroke in the past 45-90 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called finerenone can reduce scarring in the heart and improve heart function in people with heart failure who have ejection fractions of 40% or higher. You may be eligible if you've recently had heart failure symptoms requiring emergency care or medication changes.
This trial tests a medication called Finerenone to see if it can improve heart structure and function in people with both diabetic kidney disease and heart failure. If you have type 2 diabetes, kidney problems, and heart failure with preserved pumping function, this study may explore a new treatment option for you.
This trial tests a medication called finerenone to see if it helps people hospitalized for heart failure live longer and have fewer heart-related problems. It may be an option for those with a certain type of heart failure where the heart's pumping strength is mildly reduced or normal.
This study tests whether finerenone, a new type of drug, can help people with heart failure who cannot take standard steroid-based MRAs (a kind of heart medication) because of side effects or other reasons. It aims to see if it improves symptoms and is safe for you.
This trial tests two medications (finerenone and SGLT2 inhibitors) together in heart failure. It aims to see if the combination works better than either alone.
This study tests whether finerenone, a pill that helps protect the kidneys and heart, can slow down kidney decline and reduce heart failure risk in people with type 2 diabetes and chronic kidney disease.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.